Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded down 7.6% during trading on Monday following insider selling activity. The stock traded as low as $52.79 and last traded at $54.70, with a volume of 1,121,808 shares. The stock had previously closed at $59.18.

Specifically, Director Lewis Clayton Jr. Cantley sold 2,036 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $47.10, for a total transaction of $95,895.60. Following the transaction, the director now owns 91,206 shares of the company’s stock, valued at $4,295,802.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Celgene European Investment Co purchased 624,575 shares of the company’s stock in a transaction that occurred on Monday, April 24th. The shares were acquired at an average price of $49.50 per share, for a total transaction of $30,916,462.50. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 26,600 shares of company stock worth $1,394,718. 10.55% of the stock is owned by insiders.

A number of analysts recently commented on AGIO shares. Oppenheimer Holdings, Inc. set a $75.00 price target on Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, June 1st. Cann restated a “buy” rating and issued a $75.00 target price on shares of Agios Pharmaceuticals in a research note on Wednesday, April 19th. Zacks Investment Research lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, April 18th. BidaskClub upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, Janney Montgomery Scott lowered Agios Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, June 26th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $62.88.

The company has a 50-day moving average of $51.10 and a 200-day moving average of $49.19. The firm’s market capitalization is $2.79 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.56) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.80) by $0.24. The business had revenue of $10.51 million for the quarter, compared to analysts’ expectations of $9.65 million. Agios Pharmaceuticals had a negative return on equity of 71.20% and a negative net margin of 491.54%. The business’s quarterly revenue was down 66.4% on a year-over-year basis. During the same period last year, the firm earned ($0.64) earnings per share. On average, equities analysts predict that Agios Pharmaceuticals, Inc. will post ($6.44) EPS for the current year.

Large investors have recently bought and sold shares of the stock. State Street Corp boosted its stake in Agios Pharmaceuticals by 13.8% in the fourth quarter. State Street Corp now owns 1,240,585 shares of the biopharmaceutical company’s stock worth $51,772,000 after buying an additional 150,244 shares in the last quarter. Norges Bank acquired a new stake in Agios Pharmaceuticals during the fourth quarter worth approximately $8,246,000. Teachers Advisors LLC boosted its stake in Agios Pharmaceuticals by 22.7% in the fourth quarter. Teachers Advisors LLC now owns 29,592 shares of the biopharmaceutical company’s stock worth $1,235,000 after buying an additional 5,467 shares in the last quarter. Opus Point Partners Management LLC boosted its stake in Agios Pharmaceuticals by 1.5% in the fourth quarter. Opus Point Partners Management LLC now owns 55,524 shares of the biopharmaceutical company’s stock worth $2,317,000 after buying an additional 832 shares in the last quarter. Finally, Creative Planning boosted its stake in Agios Pharmaceuticals by 10.2% in the first quarter. Creative Planning now owns 16,482 shares of the biopharmaceutical company’s stock worth $963,000 after buying an additional 1,528 shares in the last quarter. 83.66% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Price Down 7.6% After Insider Selling” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/07/16/agios-pharmaceuticals-inc-nasdaqagio-stock-price-down-7-6-after-insider-selling.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.